Published in:
01-08-2008 | Editorial
Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications
Authors:
Manolis Heliotis, Eleftherios Tsiridis
Published in:
Arthritis Research & Therapy
|
Issue 4/2008
Login to get access
Abstract
Bone morphogenetic proteins (BMPs) are expressed during osteogenesis and their action is regulated by corresponding BMP inhibitors. Chordin (a well recognized BMP inhibitor) and BMP-2 are expressed during osteogenic differentiation of human mesenchymal stem cells. Chordin inhibition induces human mesenchymal stem cell differentiation and reduces their proliferation by increasing BMP-2 bioavailability. The potential of suppressing BMP inhibitors is emerging as a biological therapeutic target in bone tissue engineering, because it results in an unopposed synergy between the various growth factors that are involved in osteogenesis, within their physiological milieu.